GlassScriptPhysician profile
Vanessa E Schlauderaff
NPI 1336685080
$2,089.23
in general payments reported to CMS, 2019-2025
15 companies · $714 in 2025
The $714 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $818 · 2022: $247 · 2023: $164 · 2024: $146 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $680.57 | 2021-2025 | Eterna, Proclaim |
| Indivior INC. | $326.64 | 2022-2025 | Sublocade |
| Braeburn INC. | $291.50 | 2023-2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $191.97 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $125.11 | 2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $103.46 | 2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $96.04 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $83.58 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $41.64 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Ferring Pharmaceuticals INC. | $39.34 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $32.59 | 2021 | |
| Pfizer INC. | $25.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Schlauderaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.